Powder bergamot juice attenuates skeletal muscle complications in an experimental model of metabolic syndrome

作者：Luís Eduardo Sormani, Jordanna Cruzeiro, Matheus Antônio Filiol Belin, Marina de Paula Salomé dos Santos, Juliana Silva [UNESP] Siqueira, Taynara Aparecida Vieira, Núbia Alves Grandini, M. D TANGANINI, Thiago Luiz Novaga Palacio, Guilherme Ribeiro Romualdo, Giancarlo Aldini, Camila Renata Corrêa · 发表于：Molecular and Cellular Endocrinology · 年份：2026 · DOI：10.1016/j.mce.2026.112828 · 被引用次数：1 · 研究领域：Diabetes, Cardiovascular Risks, and Lipoproteins、Gout, Hyperuricemia, Uric Acid、Pharmacology and Obesity Treatment

Metabolic syndrome (MetS) promotes skeletal muscle complications, which can impair glucose uptake and contribute to the development of diabetes. In contrast, powder bergamot juice (PBJ) possesses bioactive compounds with potential therapeutic applications. To evaluate the effects of PBJ on skeletal muscle complications in an experimental model of metabolic syndrome. Male Wistar rats were fed a control diet (n=20) or a high-sugar fat diet (n=20) with 25% sucrose in drinking water (w/v) for 20 weeks to induce MetS. After this period, animals were then redistributed into two groups (n=7 each): MetS and MetS + PBJ. PBJ was administered by gavage at 250 mg/kg daily for 10 weeks. Systemic metabolic parameters were measured, and lipid content, fatty acid profile, inflammatory and oxidative stress biomarkers, insulin signaling proteins, and histological outcomes were evaluated in the quadriceps. PBJ treatment significantly attenuated systemic adiposity and dyslipidemia. In the quadriceps, PBJ markedly reduced triglyceride accumulation and modulated the fatty acid composition, lowering saturated fatty acid (SFA) levels and increasing the desaturation index. Oxidative stress markers, including malondialdehyde, advanced oxidation protein products, and protein carbonylation, were reduced, while antioxidant defenses were enhanced by upregulating nuclear factor erythroid 2-related factor 2 (NRF-2) signaling. Pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-α) and interleukin-6 ...